The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Re: Magnetic Resonance Imaging and Mammography in Women With a Hereditary Risk of Breast Cancer
Open accessAbstract
In a recent report, Stoutjesdijk et al. (1) determined that the operating characteristics of magnetic resonance imaging (MRI) were superior to mammography in a cohort of women, predominantly less than 50 years of age, who were at high risk for breast cancer. Similarly, other studies have found that mammography is a suboptimal screening method in BRCA1/2 mutation carriers (2,3) and that MRI may be superior (4,5). We examined the sensitivity of mammography in a retrospective cohort of Ashkenazi Jewish women who were diagnosed with primary invasive breast cancer at age less than 65 years at one institution in Montreal, Canada, between 1980 and 1995 and who were tested for the three Ashkenazi Jewish founder mutations in BRCA1/2. Details of the mammogram performed before surgery were obtained by chart review by two physicians who were blinded to the BRCA1/2 status of the patients. We used Fisher's exact test and the Mann–Whitney rank-sum test to assess the statistical significance of our results. Mammography reports were available for 161 patients. Nineteen and four patients had mutations in BRCA1 or BRCA2, respectively. BRCA1/2 mutation carriers (hereafter “BRCA1/2 carriers”) were younger (median age, 45.8 years versus 54.3 years; P = .02) and had larger tumors at diagnosis (median tumor size, 1.9 cm versus 1.4 cm; P = .05) than noncarriers, but there was no difference in the median interval between mammography and the surgical diagnosis of breast cancer between the two groups (13 versus 11 days for BRCA1/2 carriers and noncarriers, respectively; P = .99). Suspicious lesions were found in 15 (65.2%) of 23 of the BRCA1/2 carriers and in 119 (86.2%) of 138 of the noncarriers (P = .03). We stratified the data by tumor size (≤2 cm versus >2 cm) or age at diagnosis (≤50 years versus >50 years). When BRCA1/2 carriers were compared with noncarriers, there was no statistically significant difference in the number of detectable cancers if the cancers were greater than 2 cm (P = .65) or the patients were greater than 50 years of age (P = .53). However, breast cancers less than or equal to 2 cm in size occurring in BRCA1/2 carriers (median cancer size, 1.3 cm) were statistically significantly less likely to be detectable than similar-sized cancers in noncarriers (median cancer size, 1.2 cm) (six [46%] of 13 versus 96 [89%] of 108; P<.001). In women diagnosed at age 50 years or less with breast cancers less than or equal to 2 cm in size, only two (25%) of eight breast cancers were detected in BRCA1 mutation carriers compared with 27 (77%) of 35 in noncarriers (P = .009). Although it is uncertain why breast cancers occurring in BRCA1/2 carriers were less detectable by mammography than those occurring in noncarriers, one likely explanation is that the smooth, noninfiltrative edge of many BRCA1/2-related breast cancers (6) reduces their mammographic detectability. Of interest, in one study of symptomatic women who underwent mammography, medullary breast cancers were overrepresented in the false-negative group (5.5%) when compared with the true-positive group (0.8%) (7). Other possible explanations include a deficit of ductal carcinoma in situ (6) (which could be associated with less microcalcification surrounding BRCA1-related cancers) or increased mammographic density (2). Recommendations regarding the use of mammography in BRCA1/2 carriers have not been based on clinical studies. Our data support the emerging evidence (1–5) that mammography is insensitive in detecting invasive breast cancer in BRCA1/2 carriers. Furthermore, such data suggest that, for BRCA1/2 carriers, alternative forms of early detection and an increased focus on prevention are likely to be more beneficial than a reliance on mammography as an early diagnostic tool. We thank Drs. L. R. Bégin and J. Deschênes for assistance with pathology and A.-J. Paradis and N. Hamel for technical assistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The meaning and use of the area under a receiver operating characteristic (ROC) curve.
Hanley, J. A., & McNeil, B. J. (1982) · Radiology · doi:10.1148/radiology.143.1.7063747 · Cited by 21,856
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Hanley, J. A., & McNeil, B. J. (1983) · Radiology · doi:10.1148/radiology.148.3.6878708 · Cited by 7,016
Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C., & Mulvihill, J. J. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.24.1879 · Cited by 3,334
Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301749 · Cited by 3,037
The Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 among Ashkenazi Jews
Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,281
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer
Hartmann, L. C., Schaid, D. J., Woods, J. E., Crotty, T. P., Myers, J. L., Arnold, P. G., Petty, P. M., Sellers, T. A., Johnson, J. L., McDonnell, S. K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400201 · Cited by 1,423
Kuhl, C. K., Mielcareck, P., Klaschik, S., Leutner, C., Wardelmann, E., Gieseke, J., & Schild, H. H. (1999) · Radiology · doi:10.1148/radiology.211.1.r99ap38101 · Cited by 1,277
Cited by
Kriege, M., Brekelmans, C. T. M., Boetes, C., Besnard, P. E., Zonderland, H. M., Obdeijn, I. M., Manoliu, R. A., Kok, T., Peterse, H., Tilanus-Linthorst, M. M. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031759 · Cited by 1,687
American Cancer Society Guidelines for the Early Detection of Cancer
Smith, R. A., Cokkinides, V., von Eschenbach, A. C., Levin, B., Cohen, C., Runowicz, C. D., Sener, S., Saslow, D., & Eyre, H. J. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.1.8 · Cited by 1,588
Kuhl, C. K., Schrading, S., Leutner, C. C., Morakkabati-Spitz, N., Wardelmann, E., Fimmers, R., Kuhn, W., & Schild, H. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.4960 · Cited by 1,147
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,112
Elmore, J. G. (2005) · JAMA · doi:10.1001/jama.293.10.1245 · Cited by 1,075
Metadata
- Authors
- Goffin, J., Chappuis, P. O., Wong, N., & Foulkes, W. D.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-11-21
- Volume
- 93
- Issue
- 22
- Pages
- 1754-1754
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2085666802
- Cited by
- 284
- References
- 42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Re: Magnetic Resonance Imaging and Mammography in Women With a Hereditary Risk of Breast Cancer. https://app.cochat.ai/papers/10.1093/jnci/93.22.1754
- The paper
- Goffin, J., Chappuis, P. O., Wong, N., & Foulkes, W. D. (2001). Re: Magnetic Resonance Imaging and Mammography in Women With a Hereditary Risk of Breast Cancer. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/93.22.1754
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.